Electra Therapeutics Prices $350 Million In Upsized IPO To Advance Precision Medicines For Immune Diseases And Cancer

Electra Therapeutics has priced an upsized $350 million initial public offering, giving the late clinical-stage biopharmaceutical company substantial new capital as it advances a pipeline of precision medicines for immune-mediated diseases and cancer.

The South San Francisco-based company is selling 23,333,334 shares of common stock at $15 per share, generating approximately $350 million in expected gross proceeds before underwriting discounts, commissions and other offering expenses.

Electra has also granted the underwriters a 30-day option to purchase up to an additional 3.5 million shares at the IPO price. If that option is exercised in full, it would add another $52.5 million in gross proceeds and potentially increase the total offering to approximately $402.5 million.

All of the shares in the transaction are being offered directly by Electra.

The company’s shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol ETRA on September 18, 2026. The offering is expected to close on September 21, subject to customary closing conditions.

The financing provides Electra with a sizable pool of capital as it develops a new class of medicines targeting signal regulatory proteins, or SIRPs.

SIRPs are cell-surface receptors whose expression is concentrated in particular immune-cell populations and increases when those cells become activated. Electra’s therapeutic approach is intended to selectively eliminate disease-driving immune cells while preserving normal immune function.

That strategy gives Electra a platform that could potentially address both severe immune-mediated diseases and certain cancers.

The company’s lead candidate, ipsoprubart, also known as ELA026, is a pan-SIRP monoclonal antibody currently being advanced through a global registrational program for secondary hemophagocytic lymphohistiocytosis, or sHLH.

sHLH is a severe hyperinflammatory syndrome in which uncontrolled immune activation can cause potentially life-threatening organ damage.

Electra noted that there are currently no broadly approved therapies for the condition and that survival outcomes have remained poor over the past two decades.

Ipsoprubart is designed to target and deplete the activated immune cells believed to drive the disease while seeking to preserve broader immune function.

The candidate is also being evaluated in a Phase 1 clinical trial involving patients with relapsed or refractory T-cell and natural-killer-cell malignancies, extending the potential application of Electra’s SIRP platform into oncology.

Electra’s second clinical-stage candidate, ELA822, is a SIRPγ-specific antibody being developed for a broader group of chronic T-cell-mediated immune and inflammatory diseases.

The company recently initiated a Phase 1 clinical study of ELA822, adding another clinical program to its pipeline as it enters the public markets.

The upsized IPO therefore arrives at an important development stage for Electra.

With ipsoprubart already progressing through a global registrational program and ELA822 entering early clinical development, the company is moving from a largely platform-focused biotechnology story toward one centered increasingly on clinical execution and potential regulatory milestones.

The $350 million raise also provides Electra with considerably more financial flexibility as it funds clinical trials, regulatory work, manufacturing and the broader infrastructure required to advance multiple programs simultaneously.

If the underwriters exercise their full additional-share option, the potential gross proceeds of more than $400 million would further strengthen that position.

Electra’s Nasdaq debut also gives public investors exposure to a company attempting to establish SIRP-targeted medicines as a new therapeutic approach across both immunology and oncology.

Unlike broader immunosuppressive strategies, Electra’s platform is designed around selective depletion of disease-driving cells based on the expression of specific SIRP receptors.

That precision approach could become particularly important in diseases where overactive immune cells cause significant damage but preserving the remainder of the immune system remains critical.

With its lead program already in registrational development, a second candidate entering the clinic and one of the larger biotechnology IPO financings of the year, Electra enters the public market with substantial capital to advance its next stage of clinical development.

Support: Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers for the IPO.